RVL Pharmaceuticals

RVL Pharmaceuticals FCF per Share

The Free Cash Flow per Share of RVL Pharmaceuticals (RVLPQ) as of Nov 16, 2026 is -0.39 USD. In the previous year, Free Cash Flow per Share was -0.70 USD — a change of -44.24% (higher).

FCF per Share

-0.39USD

YoY

-44.24%

Last updated:

Free Cash Flow per Share of RVL Pharmaceuticals is 2022 -0.39 USD. Free Cash Flow per Share of RVL Pharmaceuticals was 2021 -0.70 USD. It decreases by -44.24% higher compared to the previous year.

The RVL Pharmaceuticals FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2016
-0.61 USD
Jan 1, 2017
1.11 USD
Jan 1, 2018
0.64 USD
Jan 1, 2019
0.57 USD
Jan 1, 2020
0.23 USD
Jan 1, 2021
-0.70 USD
Jan 1, 2022
-0.39 USD
The RVL Pharmaceuticals FCF per Share history
YEARFCF per ShareYoY
-0.39USD-44.24%
-0.70USD-402.40%
0.23USD-59.42%
0.57USD-10.67%
0.64USD-42.72%
1.11USD-281.78%
-0.61USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RVL Pharmaceuticals Stock analysis

What does RVL Pharmaceuticals do? Osmotica Pharmaceuticals PLC is a global pharmaceutical company based in Dublin, Ireland. It was founded in 2008 and focuses on the development and marketing of specialized pharmaceutical products for the treatment of neurological and psychiatric disorders, as well as behavioral disorders. The company is divided into three business segments: the Commercial Part, the Branded Part, and the Trident Part. The Commercial Part is responsible for marketing generic pharmaceuticals and other specialty products in the USA and Canada. This includes products such as Venlafaxine ER for the treatment of depression and the Parkinson's medication Apomorphine. The Branded Part is responsible for the development and marketing of its own products. This includes products such as Osmolex ER for the treatment of Parkinson's and akathisia, as well as Ontinua ER for the treatment of fibromyalgia and neuropathies. The Trident Part of the company focuses on the development of novel ophthalmology products and other specialty products for the global market. The company has a strong commitment to clinical research and development, particularly in the development of new products for use in neurology and psychiatry. Osmotica holds a number of patents for its products and has a range of products in various stages of clinical development. The success of Osmotica is based on its business model, which relies on ongoing innovation through research and development, as well as a strong distribution network for its products. Thanks to its broad product portfolio and global presence, the company is well positioned for further growth and the expansion into new markets in the future. Overall, Osmotica Pharmaceuticals PLC is an emerging pharmaceutical company with a strong focus on the development of specialized products for neurological and psychiatric disorders, as well as behavioral disorders. The company has a broad product portfolio and is well positioned for future growth. RVL Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RVL Pharmaceuticals stock

Free Cash Flow per Share of RVL Pharmaceuticals is -0.39 USD in 2022.

Free Cash Flow per Share of RVL Pharmaceuticals changed from -0.70 USD to -0.39 USD, representing a -44.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share RVL Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — RVL Pharmaceuticals

All Key Metrics — RVL Pharmaceuticals